Clinical Trial of the Week: Weight-Loss Study for Breast Cancer Patients

By Donna Loyle, Communications Specialist, LIMR

The BWEL breast cancer clinical trial is for patients who’ve been diagnosed within the past 12 months with stage 2 or 3 breast cancer and are interested in losing weight. Researchers seek to determine if losing weight and exercising more lowers the risk of cancer recurrence.

Participants must have already completed surgery and chemotherapy if applicable. They are then randomly assigned to one of two groups. The weight-loss intervention group takes part in a telephone-based weight-loss program. The health education group receives mail or online information about breast cancer topics.

Participants complete questionnaires, take weight measurements and undergo fasting blood draws at various points during the study.

Eligibility criteria:

  • Registration must have occurred within 12 months after first histologic diagnosis.
  • Neoadjuvant subjects should have no evidence of clinical T4 disease prior to chemotherapy and surgery.
  • Bilateral BC allowed provided diagnoses are synchronous (within three months of one another and at least one of two breast carcinomas meet eligibility).
  • No history of invasive breast cancer in five years prior to study registration other than the current diagnosis (prior DCIS at any time is acceptable).Other criteria apply. Please see the website (below) for more details. This study (#A011401) is available at all Main Line Health acute care hospitals. Principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more information, visit: https://www.mainlinehealth.org/research/clinical-trials/a011401
This entry was posted in Clinician News. Bookmark the permalink.

Leave a Reply

Your email address will not be published.